Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality

Myles Wolf, Miklos Z. Molnar, Ansel P. Amaral, Maria E. Czira, Anna Rudas, Akos Ujszaszi, Istvan Kiss, Laszlo Rosivall, Janos Kosa, Peter Lakatos, Csaba Kovesdy, Istvan Mucsi

Research output: Contribution to journalArticle

178 Citations (Scopus)

Abstract

An increased circulating level of fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality, cardiovascular disease, and progression of chronic kidney disease (CKD), but its role in transplant allograft and patient survival is unknown. We tested the hypothesis that increased FGF23 is an independent risk factor for all-cause mortality and allograft loss in a prospective cohort of 984 stable kidney transplant recipients. At enrollment, estimated GFR (eGFR) was 51 ± 21 ml/min per 1.73 m2 and median C-terminal FGF23 was 28 RU/ml (interquartile range, 20 to 43 RU/ml). Higher FGF23 levels independently associated with increased risk of the composite outcome of all-cause mortality and allograft loss (full model hazard ratio: 1.46 per SD increase in logFGF23, 95% confidence interval: 1.28 to 1.68, P < 0.001). The results were similar for each component of the composite outcome and in all sensitivity analyses, including prespecified analyses of patients with baseline eGFR of 30 to 90 ml/min per 1.73 m2. In contrast, other measures of phosphorus metabolism, including serum phosphate and parathyroid hormone (PTH) levels, did not consistently associate with outcomes. We conclude that a high (or elevated) FGF23 is an independent risk factor for death and allograft loss in kidney transplant recipients.

Original languageEnglish (US)
Pages (from-to)956-966
Number of pages11
JournalJournal of the American Society of Nephrology
Volume22
Issue number5
DOIs
StatePublished - May 1 2011

Fingerprint

Allografts
Transplants
Kidney
Mortality
Parathyroid Hormone
Chronic Renal Insufficiency
Proportional Hazards Models
Phosphorus
Disease Progression
Cardiovascular Diseases
Phosphates
fibroblast growth factor 23
Confidence Intervals
Survival
Serum
Transplant Recipients

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Wolf, M., Molnar, M. Z., Amaral, A. P., Czira, M. E., Rudas, A., Ujszaszi, A., ... Mucsi, I. (2011). Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. Journal of the American Society of Nephrology, 22(5), 956-966. https://doi.org/10.1681/ASN.2010080894

Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. / Wolf, Myles; Molnar, Miklos Z.; Amaral, Ansel P.; Czira, Maria E.; Rudas, Anna; Ujszaszi, Akos; Kiss, Istvan; Rosivall, Laszlo; Kosa, Janos; Lakatos, Peter; Kovesdy, Csaba; Mucsi, Istvan.

In: Journal of the American Society of Nephrology, Vol. 22, No. 5, 01.05.2011, p. 956-966.

Research output: Contribution to journalArticle

Wolf, M, Molnar, MZ, Amaral, AP, Czira, ME, Rudas, A, Ujszaszi, A, Kiss, I, Rosivall, L, Kosa, J, Lakatos, P, Kovesdy, C & Mucsi, I 2011, 'Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality', Journal of the American Society of Nephrology, vol. 22, no. 5, pp. 956-966. https://doi.org/10.1681/ASN.2010080894
Wolf, Myles ; Molnar, Miklos Z. ; Amaral, Ansel P. ; Czira, Maria E. ; Rudas, Anna ; Ujszaszi, Akos ; Kiss, Istvan ; Rosivall, Laszlo ; Kosa, Janos ; Lakatos, Peter ; Kovesdy, Csaba ; Mucsi, Istvan. / Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. In: Journal of the American Society of Nephrology. 2011 ; Vol. 22, No. 5. pp. 956-966.
@article{72b64fb8475c461786bd184d41d0f501,
title = "Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality",
abstract = "An increased circulating level of fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality, cardiovascular disease, and progression of chronic kidney disease (CKD), but its role in transplant allograft and patient survival is unknown. We tested the hypothesis that increased FGF23 is an independent risk factor for all-cause mortality and allograft loss in a prospective cohort of 984 stable kidney transplant recipients. At enrollment, estimated GFR (eGFR) was 51 ± 21 ml/min per 1.73 m2 and median C-terminal FGF23 was 28 RU/ml (interquartile range, 20 to 43 RU/ml). Higher FGF23 levels independently associated with increased risk of the composite outcome of all-cause mortality and allograft loss (full model hazard ratio: 1.46 per SD increase in logFGF23, 95{\%} confidence interval: 1.28 to 1.68, P < 0.001). The results were similar for each component of the composite outcome and in all sensitivity analyses, including prespecified analyses of patients with baseline eGFR of 30 to 90 ml/min per 1.73 m2. In contrast, other measures of phosphorus metabolism, including serum phosphate and parathyroid hormone (PTH) levels, did not consistently associate with outcomes. We conclude that a high (or elevated) FGF23 is an independent risk factor for death and allograft loss in kidney transplant recipients.",
author = "Myles Wolf and Molnar, {Miklos Z.} and Amaral, {Ansel P.} and Czira, {Maria E.} and Anna Rudas and Akos Ujszaszi and Istvan Kiss and Laszlo Rosivall and Janos Kosa and Peter Lakatos and Csaba Kovesdy and Istvan Mucsi",
year = "2011",
month = "5",
day = "1",
doi = "10.1681/ASN.2010080894",
language = "English (US)",
volume = "22",
pages = "956--966",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality

AU - Wolf, Myles

AU - Molnar, Miklos Z.

AU - Amaral, Ansel P.

AU - Czira, Maria E.

AU - Rudas, Anna

AU - Ujszaszi, Akos

AU - Kiss, Istvan

AU - Rosivall, Laszlo

AU - Kosa, Janos

AU - Lakatos, Peter

AU - Kovesdy, Csaba

AU - Mucsi, Istvan

PY - 2011/5/1

Y1 - 2011/5/1

N2 - An increased circulating level of fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality, cardiovascular disease, and progression of chronic kidney disease (CKD), but its role in transplant allograft and patient survival is unknown. We tested the hypothesis that increased FGF23 is an independent risk factor for all-cause mortality and allograft loss in a prospective cohort of 984 stable kidney transplant recipients. At enrollment, estimated GFR (eGFR) was 51 ± 21 ml/min per 1.73 m2 and median C-terminal FGF23 was 28 RU/ml (interquartile range, 20 to 43 RU/ml). Higher FGF23 levels independently associated with increased risk of the composite outcome of all-cause mortality and allograft loss (full model hazard ratio: 1.46 per SD increase in logFGF23, 95% confidence interval: 1.28 to 1.68, P < 0.001). The results were similar for each component of the composite outcome and in all sensitivity analyses, including prespecified analyses of patients with baseline eGFR of 30 to 90 ml/min per 1.73 m2. In contrast, other measures of phosphorus metabolism, including serum phosphate and parathyroid hormone (PTH) levels, did not consistently associate with outcomes. We conclude that a high (or elevated) FGF23 is an independent risk factor for death and allograft loss in kidney transplant recipients.

AB - An increased circulating level of fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality, cardiovascular disease, and progression of chronic kidney disease (CKD), but its role in transplant allograft and patient survival is unknown. We tested the hypothesis that increased FGF23 is an independent risk factor for all-cause mortality and allograft loss in a prospective cohort of 984 stable kidney transplant recipients. At enrollment, estimated GFR (eGFR) was 51 ± 21 ml/min per 1.73 m2 and median C-terminal FGF23 was 28 RU/ml (interquartile range, 20 to 43 RU/ml). Higher FGF23 levels independently associated with increased risk of the composite outcome of all-cause mortality and allograft loss (full model hazard ratio: 1.46 per SD increase in logFGF23, 95% confidence interval: 1.28 to 1.68, P < 0.001). The results were similar for each component of the composite outcome and in all sensitivity analyses, including prespecified analyses of patients with baseline eGFR of 30 to 90 ml/min per 1.73 m2. In contrast, other measures of phosphorus metabolism, including serum phosphate and parathyroid hormone (PTH) levels, did not consistently associate with outcomes. We conclude that a high (or elevated) FGF23 is an independent risk factor for death and allograft loss in kidney transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=79955603792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955603792&partnerID=8YFLogxK

U2 - 10.1681/ASN.2010080894

DO - 10.1681/ASN.2010080894

M3 - Article

VL - 22

SP - 956

EP - 966

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -